Researchers from the George Washington University have uncovered promising evidence in an animal study that shows setmelanotide, an FDA-approved medication for a rare genetic obesity disorder, may offer a pathway for treating a life-threatening form of sleep-disordered breathing called Obesity Hypoventilation Syndrome.